Alden Global Capital adds Novavax (NVAX) to its portfolio

Novavax (NVAX) : Alden Global Capital added new position in Novavax during the most recent quarter end. The investment management firm now holds 1,000,000 shares of Novavax which is valued at $4.4 Million , the company said in a statement filed on May 13, 2016 with the SEC.Novavax makes up approximately 3.37% of Alden Global Capital’s portfolio.

Other Hedge Funds, Including , Wellington Management Group Llp boosted its stake in NVAX in the latest quarter, The investment management firm added 3,849,585 additional shares and now holds a total of 12,711,938 shares of Novavax which is valued at $56.1 Million. Novavax makes up approx 0.01% of Wellington Management Group Llp’s portfolio.Employees Retirement System Of Texas boosted its stake in NVAX in the latest quarter, The investment management firm added 45,000 additional shares and now holds a total of 286,000 shares of Novavax which is valued at $1.3 Million. Novavax makes up approx 0.02% of Employees Retirement System Of Texas’s portfolio.State Board Of Administration Of Florida Retirement System boosted its stake in NVAX in the latest quarter, The investment management firm added 7,840 additional shares and now holds a total of 141,673 shares of Novavax which is valued at $653,113.Stoneridge Investment Partners reduced its stake in NVAX by selling 21,655 shares or 9.36% in the most recent quarter. The Hedge Fund company now holds 209,697 shares of NVAX which is valued at $1.1 Million. Novavax makes up approx 0.16% of Stoneridge Investment Partners’s portfolio.

Novavax opened for trading at $5.9 and hit $6.06 on the upside on Wednesday, eventually ending the session at $5.78, with a gain of 5.09% or 0.28 points. The heightened volatility saw the trading volume jump to 1,03,77,267 shares. Company has a market cap of $1,565 M.

On the company’s financial health, Novavax reported $-0.29 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on May 4, 2016. Analyst had a consensus of $-0.27. The company had revenue of $4.20 million for the quarter, compared to analysts expectations of $10.02 million. The company’s revenue was down -57.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.10 EPS.

Many Wall Street Analysts have commented on Novavax. Chardan Capital Markets Initiated Novavax on Apr 4, 2016 to “Neutral”, Price Target of the shares are set at $5.75.

Novavax Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV) seasonal influenza pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications Matrix-M is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases including Middle East respiratory syndrome (MERS).

Leave a Reply

Novavax - Is it time to Sell?

Top Brokerage Firms are advising their investors on Novavax. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.